# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational t...
Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:PRTA) with a Overweight.
HC Wainwright & Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $90 price target.
JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price targ...
RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and lowers the price target f...
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.2...